News Releases
Viewing Category: Atripla
-
PRINCETON, N.J. and FOSTER CITY, Calif. - September 28, 2006
Bristol-Myers Squibb and Gilead Sciences establish agreement to commercialize Atripla™ (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada
If Approved, Product Would Be the First Once-Daily Single Tablet Regimen for HIV-1 Infection in Adults in Canada
